Loading...
NPI 1164019725 · Las Vegas, NV · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Dna Analytical Laboratory Lv LLC is a clinical medical laboratory provider located in Las Vegas, Nevada. This profile covers 1 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Dna Analytical Laboratory Lv LLC |
| Address | 4310 Cameron St Ste 9 |
| City | Las Vegas |
| State | NV |
| ZIP | 89103 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 29, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $24.9M |
| Medicaid | $8.9K |
This provider’s Medicare footprint is by far the dominant revenue source: lifetime Medicare revenue is reported as $24.9M compared with lifetime Medicaid revenue of $8.9K, indicating an effectively single‑payer business scale concentrated on Medicare billing. The NPI was enumerated on 2020-12-29 (~6 years ago), so the account activity aligns with post‑2020 pandemic-era service lines.
The operation appears to be overwhelmingly focused on COVID-19 testing services. The top Medicare code is K1034 (provision of nonprescription self‑administered/self‑collected COVID-19 tests) and the top Medicaid codes are the same K1034 plus a small volume of 87637 (multiplex molecular testing for SARS‑CoV‑2, influenza A/B, RSV), indicating primary activity around test provision and some laboratory molecular testing capacity.
Medicare revenue concentration is extreme: the precomputed top three Medicare codes account for 100.0% of this provider's total Medicare revenue, and K1034 alone is listed with 2.1M claims, $12 avg paid/claim, and $25.4M revenue. That K1034 volume ranks #14 of 30143 providers nationally (100th percentile; extreme outlier), making the provider a substantial outlier on this single code.
Medicaid billing is similarly concentrated: the precomputed top three Medicaid codes account for 100.0% of Medicaid revenue, with K1034 representing $5.6K revenue from 5.6K claims ($1 avg paid/claim) and accounting for 84.9% of this provider's total Medicaid revenue. The K1034 Medicaid volume ranks #1 of 28 providers in-state (100th percentile; extreme outlier), while the other Medicaid activity is limited to 87637 (18 claims, $990 revenue, 15.1% of Medicaid revenue) which ranks #16 of 16 in-state (0th percentile; typical, unremarkable volume).
Competitive standing is highly code-specific: for K1034 the provider is a dominant national outlier (rank #14/30143, 100th percentile) and also the top in-state Medicaid filer (rank #1/28, 100th percentile), but outside of K1034 the provider shows minimal participation. This pattern describes a market position that is very strong on OTC/self‑administered COVID test provisioning but limited in broader laboratory service presence.
Payment dynamics diverge sharply by payer for the same code: K1034 is listed with $12 avg paid/claim on Medicare versus $1 avg paid/claim on Medicaid, reflecting substantial reimbursement differences for the same service across payers. Analysts should note this pronounced payer payment gap when modeling revenue sensitivity or negotiating rates tied to similar services.
The combination of very high claim volume for a single code (2.1M K1034 claims on Medicare) and near‑exclusive revenue concentration (top 3 Medicare codes = 100.0% of Medicare revenue; top 3 Medicaid codes = 100.0% of Medicaid revenue) suggests limited service diversification. This concentration creates operational dependence on the reimbursement environment and policy for K1034 and related COVID testing codes, making the provider's financials sensitive to any changes in coverage or payment rules.
The NPI enumeration date of 2020-12-29 (~6 years ago) indicates the provider’s commercial presence was established during the pandemic period, which is consistent with the business model heavily weighted to COVID testing codes. That timing likely explains the rapid accumulation of high K1034 volumes on both Medicare and Medicaid billing streams.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,114,800 | $10 | $25.4M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 1 | 230 | 550 | $10 | $117.3K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 5,560 | $1 | $5.6K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 20 | $60 | $990 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 16 | 20 | 610 | $50 | $73.2K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1 | 30 | 100 | $10 | $4.2K |
Other providers in the same ZIP code as Dna Analytical Laboratory Lv LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.